Oct 22nd 2012 - Edison Investment Research today published a report on quickview entitled "It’s Go Time". In summary, the report says:
Ironwood and its US partner Forest Labs are poised for one of the biggest new product launches in years. Linzess (linaclotide), FDA-approved in August and set for US launch in December, addresses the millions of patients globally with chronic constipation disorders so has the potential to achieve >$1bn in peak annual sales. Ironwood’s $1.4bn market cap reflects already high investor expectations, so near-term share price gains largely depend on how Linzess performs out of the gates.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »